Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172184696> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W3172184696 endingPage "5537" @default.
- W3172184696 startingPage "5537" @default.
- W3172184696 abstract "5537 Background: ARIEL3 is a placebo-controlled randomized trial of the PARP inhibitor (PARPi) rucaparib as maintenance treatment in HGOC patients (pts) who responded to the latest line of platinum therapy (NCT01968213). Rucaparib improved progression-free survival (PFS) across all predefined subgroups. Here, we present an exploratory analysis of clinical and molecular characteristics associated with exceptional benefit from rucaparib. Methods: Pts were randomized 2:1 to receive rucaparib 600 mg BID or placebo. At the data cutoff of Dec 31, 2019, 33/375 (9%) and 1/189 (0.5%) pts were still ongoing and receiving rucaparib or placebo, respectively. Molecular features (genomic alterations, BRCA1 promoter methylation) and baseline clinical characteristics were compared between pts who derived exceptional benefit (PFS ≥2 yrs), and those with disease progression on first scan (≈12 wks; the short-term [ST] subgroup) within each treatment arm. Results: Of 564 pts, 83 (15%) showed exceptional benefit: 79/375 (21%) in the rucaparib arm and 4/189 (2%) in the placebo arm. Within the rucaparib arm, exceptional benefit pts had more favorable clinical prognostic factors at baseline compared with the ST subgroup (Table). While BRCA mutations were enriched in the rucaparib exceptional benefit subgroup, 34/79 (43%) of these pts were BRCA wild type. Among other biomarkers, RAD51C/D mutations were associated with exceptional benefit; low genome-wide loss of heterozygosity was enriched within the ST subgroup; and high BRCA1 methylation was present at similar fractions. Trends were similar in the placebo arm (Table). Conclusions: Exceptional benefit in ARIEL3 was more common in, but not exclusive to, pts with favorable clinical characteristics and known mechanisms of PARPi sensitivity. Our results suggest that rucaparib can deliver exceptional benefit to a diverse set of HGOC pts. Clinical trial information: NCT01968213. [Table: see text]" @default.
- W3172184696 created "2021-06-22" @default.
- W3172184696 creator A5009234043 @default.
- W3172184696 creator A5009816218 @default.
- W3172184696 creator A5018801649 @default.
- W3172184696 creator A5021359849 @default.
- W3172184696 creator A5026048739 @default.
- W3172184696 creator A5030217250 @default.
- W3172184696 creator A5032801379 @default.
- W3172184696 creator A5032881252 @default.
- W3172184696 creator A5051505642 @default.
- W3172184696 creator A5052709676 @default.
- W3172184696 creator A5054602117 @default.
- W3172184696 creator A5056423529 @default.
- W3172184696 creator A5057002841 @default.
- W3172184696 creator A5061939825 @default.
- W3172184696 creator A5064757320 @default.
- W3172184696 creator A5066888430 @default.
- W3172184696 creator A5067053417 @default.
- W3172184696 creator A5072712459 @default.
- W3172184696 creator A5079383798 @default.
- W3172184696 creator A5082234321 @default.
- W3172184696 date "2021-05-20" @default.
- W3172184696 modified "2023-10-17" @default.
- W3172184696 title "Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)." @default.
- W3172184696 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.5537" @default.
- W3172184696 hasPublicationYear "2021" @default.
- W3172184696 type Work @default.
- W3172184696 sameAs 3172184696 @default.
- W3172184696 citedByCount "0" @default.
- W3172184696 crossrefType "journal-article" @default.
- W3172184696 hasAuthorship W3172184696A5009234043 @default.
- W3172184696 hasAuthorship W3172184696A5009816218 @default.
- W3172184696 hasAuthorship W3172184696A5018801649 @default.
- W3172184696 hasAuthorship W3172184696A5021359849 @default.
- W3172184696 hasAuthorship W3172184696A5026048739 @default.
- W3172184696 hasAuthorship W3172184696A5030217250 @default.
- W3172184696 hasAuthorship W3172184696A5032801379 @default.
- W3172184696 hasAuthorship W3172184696A5032881252 @default.
- W3172184696 hasAuthorship W3172184696A5051505642 @default.
- W3172184696 hasAuthorship W3172184696A5052709676 @default.
- W3172184696 hasAuthorship W3172184696A5054602117 @default.
- W3172184696 hasAuthorship W3172184696A5056423529 @default.
- W3172184696 hasAuthorship W3172184696A5057002841 @default.
- W3172184696 hasAuthorship W3172184696A5061939825 @default.
- W3172184696 hasAuthorship W3172184696A5064757320 @default.
- W3172184696 hasAuthorship W3172184696A5066888430 @default.
- W3172184696 hasAuthorship W3172184696A5067053417 @default.
- W3172184696 hasAuthorship W3172184696A5072712459 @default.
- W3172184696 hasAuthorship W3172184696A5079383798 @default.
- W3172184696 hasAuthorship W3172184696A5082234321 @default.
- W3172184696 hasConcept C104317684 @default.
- W3172184696 hasConcept C126322002 @default.
- W3172184696 hasConcept C142724271 @default.
- W3172184696 hasConcept C143998085 @default.
- W3172184696 hasConcept C182979987 @default.
- W3172184696 hasConcept C204787440 @default.
- W3172184696 hasConcept C27081682 @default.
- W3172184696 hasConcept C2779138821 @default.
- W3172184696 hasConcept C535046627 @default.
- W3172184696 hasConcept C54355233 @default.
- W3172184696 hasConcept C71924100 @default.
- W3172184696 hasConcept C82381507 @default.
- W3172184696 hasConcept C86803240 @default.
- W3172184696 hasConceptScore W3172184696C104317684 @default.
- W3172184696 hasConceptScore W3172184696C126322002 @default.
- W3172184696 hasConceptScore W3172184696C142724271 @default.
- W3172184696 hasConceptScore W3172184696C143998085 @default.
- W3172184696 hasConceptScore W3172184696C182979987 @default.
- W3172184696 hasConceptScore W3172184696C204787440 @default.
- W3172184696 hasConceptScore W3172184696C27081682 @default.
- W3172184696 hasConceptScore W3172184696C2779138821 @default.
- W3172184696 hasConceptScore W3172184696C535046627 @default.
- W3172184696 hasConceptScore W3172184696C54355233 @default.
- W3172184696 hasConceptScore W3172184696C71924100 @default.
- W3172184696 hasConceptScore W3172184696C82381507 @default.
- W3172184696 hasConceptScore W3172184696C86803240 @default.
- W3172184696 hasIssue "15_suppl" @default.
- W3172184696 hasLocation W31721846961 @default.
- W3172184696 hasOpenAccess W3172184696 @default.
- W3172184696 hasPrimaryLocation W31721846961 @default.
- W3172184696 hasRelatedWork W1743485 @default.
- W3172184696 hasRelatedWork W17587699 @default.
- W3172184696 hasRelatedWork W21201042 @default.
- W3172184696 hasRelatedWork W2544042 @default.
- W3172184696 hasRelatedWork W2855694 @default.
- W3172184696 hasRelatedWork W2880624 @default.
- W3172184696 hasRelatedWork W3251518 @default.
- W3172184696 hasRelatedWork W7268927 @default.
- W3172184696 hasRelatedWork W7720014 @default.
- W3172184696 hasRelatedWork W4714080 @default.
- W3172184696 hasVolume "39" @default.
- W3172184696 isParatext "false" @default.
- W3172184696 isRetracted "false" @default.
- W3172184696 magId "3172184696" @default.
- W3172184696 workType "article" @default.